Literature DB >> 26976945

Photolabeling a Nicotinic Acetylcholine Receptor (nAChR) with an (α4)3(β2)2 nAChR-Selective Positive Allosteric Modulator.

Ayman K Hamouda1, Farah Deba2, Ze-Jun Wang2, Jonathan B Cohen2.   

Abstract

Positive allosteric modulators (PAMs) of nicotinic acetylcholine (ACh) receptors (nAChRs) have potential clinical applications in the treatment of nicotine dependence and many neuropsychiatric conditions associated with decreased brain cholinergic activity, and 3-(2-chlorophenyl)-5-(5-methyl-1-(piperidin-4-yl)-1H-pyrrazol-4-yl)isoxazole (CMPI) has been identified as a PAM selective for neuronal nAChRs containing theα4 subunit. In this report, we compare CMPI interactions with low-sensitivity (α4)3(β2)2 and high-sensitivity (α4)2(β2)3 nAChRs, and with muscle-type nAChRs. In addition, we use the intrinsic reactivity of [(3)H]CMPI upon photolysis at 312 nm to identify its binding sites inTorpedonAChRs. Recording fromXenopusoocytes, we found that CMPI potentiated maximally the responses of (α4)3(β2)2nAChR to 10μM ACh (EC10) by 400% and with anEC50of ∼1µM. CMPI produced a left shift of the ACh concentration-response curve without altering ACh efficacy. In contrast, CMPI inhibited (∼35% at 10µM) ACh responses of (α4)2(β2)3nAChRs and fully inhibited human muscle andTorpedonAChRs with IC50values of ∼0.5µM. Upon irradiation at 312 nm, [(3)H]CMPI photoincorporated into eachTorpedo[(α1)2β1γδ] nAChR subunit. Sequencing of peptide fragments isolated from [(3)H]CMPI-photolabeled nAChR subunits established photolabeling of amino acids contributing to the ACh binding sites (αTyr(190),αTyr(198),γTrp(55),γTyr(111),γTyr(117),δTrp(57)) that was fully inhibitable by agonist and lower-efficiency, state-dependent [(3)H]CMPI photolabeling within the ion channel. Our results establish that CMPI is a potent potentiator of nAChRs containing anα4:α4 subunit interface, and that its intrinsic photoreactivy makes it of potential use to identify its binding sites in the (α4)3(β2)2nAChR.
Copyright © 2016 by The American Society for Pharmacology and Experimental Therapeutics.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26976945      PMCID: PMC4851301          DOI: 10.1124/mol.116.103341

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  49 in total

1.  Single-channel and structural foundations of neuronal α7 acetylcholine receptor potentiation.

Authors:  Corrie J B daCosta; Chris R Free; Jeremías Corradi; Cecilia Bouzat; Steven M Sine
Journal:  J Neurosci       Date:  2011-09-28       Impact factor: 6.167

2.  Additional acetylcholine (ACh) binding site at alpha4/alpha4 interface of (alpha4beta2)2alpha4 nicotinic receptor influences agonist sensitivity.

Authors:  Simone Mazzaferro; Naïl Benallegue; Anna Carbone; Federica Gasparri; Ranjit Vijayan; Philip C Biggin; Mirko Moroni; Isabel Bermudez
Journal:  J Biol Chem       Date:  2011-07-14       Impact factor: 5.157

Review 3.  Structural and functional diversity of native brain neuronal nicotinic receptors.

Authors:  Cecilia Gotti; Francesco Clementi; Alice Fornari; Annalisa Gaimarri; Stefania Guiducci; Irene Manfredi; Milena Moretti; Patrizia Pedrazzi; Luca Pucci; Michele Zoli
Journal:  Biochem Pharmacol       Date:  2009-05-27       Impact factor: 5.858

4.  Potentiation of alpha7 nicotinic acetylcholine receptors via an allosteric transmembrane site.

Authors:  Gareth T Young; Ruud Zwart; Alison S Walker; Emanuele Sher; Neil S Millar
Journal:  Proc Natl Acad Sci U S A       Date:  2008-09-12       Impact factor: 11.205

5.  Unraveling the high- and low-sensitivity agonist responses of nicotinic acetylcholine receptors.

Authors:  Kasper Harpsøe; Philip K Ahring; Jeppe K Christensen; Marianne L Jensen; Dan Peters; Thomas Balle
Journal:  J Neurosci       Date:  2011-07-27       Impact factor: 6.167

Review 6.  Aliphatic diazirines as photoaffinity probes for proteins: recent developments.

Authors:  Joydip Das
Journal:  Chem Rev       Date:  2011-04-05       Impact factor: 60.622

Review 7.  Positive allosteric modulators as an approach to nicotinic acetylcholine receptor-targeted therapeutics: advantages and limitations.

Authors:  Dustin K Williams; Jingyi Wang; Roger L Papke
Journal:  Biochem Pharmacol       Date:  2011-05-14       Impact factor: 5.858

8.  Photolabeling the Torpedo nicotinic acetylcholine receptor with 4-azido-2,3,5,6-tetrafluorobenzoylcholine, a partial agonist.

Authors:  Selvanayagam Nirthanan; Michael R Ziebell; David C Chiara; Filbert Hong; Jonathan B Cohen
Journal:  Biochemistry       Date:  2005-10-18       Impact factor: 3.162

9.  Allosteric modulator Desformylflustrabromine relieves the inhibition of α2β2 and α4β2 nicotinic acetylcholine receptors by β-amyloid(1-42) peptide.

Authors:  Anshul Pandya; Jerrel L Yakel
Journal:  J Mol Neurosci       Date:  2011-03-22       Impact factor: 3.444

10.  Physostigmine and galanthamine bind in the presence of agonist at the canonical and noncanonical subunit interfaces of a nicotinic acetylcholine receptor.

Authors:  Ayman K Hamouda; Tilia Kimm; Jonathan B Cohen
Journal:  J Neurosci       Date:  2013-01-09       Impact factor: 6.167

View more
  10 in total

Review 1.  Orthosteric and allosteric potentiation of heteromeric neuronal nicotinic acetylcholine receptors.

Authors:  Jingyi Wang; Jon Lindstrom
Journal:  Br J Pharmacol       Date:  2017-03-20       Impact factor: 8.739

2.  Unraveling amino acid residues critical for allosteric potentiation of (α4)3(β2)2-type nicotinic acetylcholine receptor responses.

Authors:  Ze-Jun Wang; Farah Deba; Tasnim S Mohamed; David C Chiara; Kara Ramos; Ayman K Hamouda
Journal:  J Biol Chem       Date:  2017-04-26       Impact factor: 5.157

3.  Enantiomeric barbiturates bind distinct inter- and intrasubunit binding sites in a nicotinic acetylcholine receptor (nAChR).

Authors:  Zhiyi Yu; Jonathan B Cohen
Journal:  J Biol Chem       Date:  2017-09-06       Impact factor: 5.157

4.  Concatemers to re-investigate the role of α5 in α4β2 nicotinic receptors.

Authors:  Marie S Prevost; Hichem Bouchenaki; Nathalie Barilone; Marc Gielen; Pierre-Jean Corringer
Journal:  Cell Mol Life Sci       Date:  2020-05-29       Impact factor: 9.261

5.  Role of the Cys Loop and Transmembrane Domain in the Allosteric Modulation of α4β2 Nicotinic Acetylcholine Receptors.

Authors:  Constanza Alcaino; Maria Musgaard; Teresa Minguez; Simone Mazzaferro; Manuel Faundez; Patricio Iturriaga-Vasquez; Philip C Biggin; Isabel Bermudez
Journal:  J Biol Chem       Date:  2016-11-18       Impact factor: 5.157

6.  Reversal of Nicotine Withdrawal Signs Through Positive Allosteric Modulation of α4β2 Nicotinic Acetylcholine Receptors in Male Mice.

Authors:  Ayman K Hamouda; Asti Jackson; Deniz Bagdas; M Imad Damaj
Journal:  Nicotine Tob Res       Date:  2018-06-07       Impact factor: 4.244

Review 7.  More than Smoke and Patches: The Quest for Pharmacotherapies to Treat Tobacco Use Disorder.

Authors:  M J Moerke; L R McMahon; J L Wilkerson
Journal:  Pharmacol Rev       Date:  2020-04       Impact factor: 25.468

8.  Potentiation of (α4)2(β2)3, but not (α4)3(β2)2, nicotinic acetylcholine receptors reduces nicotine self-administration and withdrawal symptoms.

Authors:  Ayman K Hamouda; Malia R Bautista; Lois S Akinola; Yasmin Alkhlaif; Asti Jackson; Moriah Carper; Wisam B Toma; Sumanta Garai; Yen-Chu Chen; Ganesh A Thakur; Christie D Fowler; M Imad Damaj
Journal:  Neuropharmacology       Date:  2021-04-18       Impact factor: 5.273

9.  LY2087101 and dFBr share transmembrane binding sites in the (α4)3(β2)2 Nicotinic Acetylcholine Receptor.

Authors:  Farah Deba; Hamed I Ali; Abisola Tairu; Kara Ramos; Jihad Ali; Ayman K Hamouda
Journal:  Sci Rep       Date:  2018-01-19       Impact factor: 4.379

10.  Examining the Effects of (α4)3(β2)2 Nicotinic Acetylcholine Receptor-Selective Positive Allosteric Modulator on Acute Thermal Nociception in Rats.

Authors:  Farah Deba; Kara Ramos; Matthew Vannoy; Kemburli Munoz; Lois S Akinola; M Imad Damaj; Ayman K Hamouda
Journal:  Molecules       Date:  2020-06-25       Impact factor: 4.411

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.